The Cancer Immunotherapy Consortium (CIC) is a think tank consisting of industry leaders from the cancer immunotherapy space. The CIC acts as a neutral platform whereby industry representatives work together and align on important issues and collectively facilitate solutions to challenges in late-stage drug development, with the goal of accelerating patient benefit.
The CIC will convene and address topics of importance to the development of immunotherapies. Outcomes will be available to all stakeholders in the field. Immediate topics to be addressed by the group include immune-related Response Criteria (irRC) and second generation biomarkers.
Evolution of the Program
The CIC was founded in 2002 as an international association of pharmaceutical and biotechnology companies and academic institutions with a common interest in immunotherapy research and development with the ultimate goal of making cancer immunotherapies part of the standard-of-care in oncology. Following the 2011 FDA approval of ipilimumab (Yervoy®), an immune checkpoint inhibitor drug, the first milestone toward this goal was achieved. Given the substantial increase in development activity and clinical success of other immunotherapy agents that followed, and in an effort to continue to provide maximum value to the rapidly evolving field, the direction of the CIC was re-set to become a “think tank” that would convene and tackle topics of importance to the continued development of cancer immunotherapies.
The Cancer Immunotherapy Consortium is governed by an executive committee who are tasked with further developing the Consortium's mission, choosing its priority projects, and monitoring the program's overall progress.
The Cancer Immunotherapy Consortium has served the cancer immunotherapy community since 2002 and has made significant contributions to progress in the field. Through seminars, workshops, working groups, and online consensus-building projects supported by immunological and clinical data from cancer immunotherapy trials, the Consortium works to address several of the key issues facing the cancer immunotherapy field.
The CIC contributes to the creation of white papers, response documents, and peer-reviewed publications advancing novel outcomes from workshops that seek practical solutions to today's challenges in cancer immunotherapy development.
Browse Our Library